These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 12771706

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 25. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [Abstract] [Full Text] [Related]

  • 26. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A, Anastasi G, Melloni D, Frisina N.
    J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
    [Abstract] [Full Text] [Related]

  • 27. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA.
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [Abstract] [Full Text] [Related]

  • 28. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F, McKiernan J, Eastham J.
    Urol Oncol; 2006 Sep; 24(1):4-12. PubMed ID: 16414486
    [Abstract] [Full Text] [Related]

  • 29. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F, Abrahamsson PA, Miller K.
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [Abstract] [Full Text] [Related]

  • 30. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH, Yang LP, Wang LS, Zhou DF.
    Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
    [Abstract] [Full Text] [Related]

  • 33. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 34. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S, DjeDjos S, Alferos G, Deprisco C.
    Prostate Cancer Prostatic Dis; 2006 Apr; 9(1):35-8. PubMed ID: 16276350
    [Abstract] [Full Text] [Related]

  • 35. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.
    Cancer; 2002 Nov 15; 95(10):2136-44. PubMed ID: 12412167
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.